The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 5, 2010, Pages 1066-1074

  Gersh, K C ^a   Zaitsev, S ^a   Muzykantov, V ^a   Cines, D B ^a   Weisel, J W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Erythrocytes; Fibrin; Fibrinolysis; Plasminogen activators

Indexed keywords

FIBRIN; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR;

ARTICLE; CATALYSIS; CELL MOTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISSOLUTION; ERYTHROCYTE; FIBRIN CLOT; FIBRINOLYSIS; FLUORESCENCE ANALYSIS; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOCATALYSIS; DRUG EFFECTS; SOLUBILITY;

ANIMALS; BIOCATALYSIS; ERYTHROCYTES; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICROSCOPY, CONFOCAL; SOLUBILITY;

EID: 77953732621     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03802.x     Document Type: Article

References (21)

1. Selim M. Perioperative stroke. N Engl J Med 2007, 356:706-13.
2. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995, 108:312S-34S.
3. Baruah DB, Dash RN, Chaudhari MR, Kadam SS. Plasminogen activators: a comparison. Vascul Pharmacol 2006, 44:1-9.
4. Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 2003, 21:891-6.
5. Murciano JC, Higazi AA, Cines DB, Muzykantov VR. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Control Release 2009, 139:190-6.
6. Ganguly K, Krasik T, Medinilla S, Bdeir K, Cines DB, Muzykantov VR, Murciano JC. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther 2005, 312:1106-13.
7. Danielyan K, Ganguly K, Ding BS, Atochin D, Zaitsev S, Murciano JC, Huang PL, Kasner SE, Cines DB, Muzykantov VR. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation 2008, 118:1442-9.
8. Ganguly K, Goel MS, Krasik T, Bdeir K, Diamond SL, Cines DB, Muzykantov VR, Murciano JC. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther 2006, 316:1130-6.
9. Zaitsev S, Danielyan K, Murciano JC, Ganguly K, Krasik T, Taylor RP, Pincus S, Jones S, Cines DB, Muzykantov VR. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 2006, 108:1895-902.
10. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005, 129:307-21.
11. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008, 6:161-80.
12. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000, 20:1354-61.
13. Collet JP, Lesty C, Montalescot G, Weisel JW. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003, 278:21331-5.
14. Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes. Thromb Haemost 2009, 102:1169-75.
15. Ding BS, Hong N, Murciano JC, Ganguly K, Gottstein C, Christofidou-Solomidou M, Albelda SM, Fisher AB, Cines DB, Muzykantov VR. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 2008, 111:1999-2006.
16. Kina T, Ikuta K, Takayama E, Wada K, Majumdar AS, Weissman IL, Katsura Y. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol 2000, 109:280-7.
17. Zaitsev S, Spitzer D, Murciano J-C, Ding B-S, Tliba S, Kowalska MA, Bdeir K, Kuo A, Stepanova V, Atkinson JP, Poncz M, Cines DB, Muzykantov VR. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther 2009, http://dx.doi.org/10.1124/jpet.109.159194, DOI:
18. Gregory TR. Cell Size Database http://www.genomesize.com/cellsize/, 2005
19. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996, 271:2133-8.
20. Ganguly K, Murciano JC, Westrick R, Leferovich J, Cines DB, Muzykantov VR. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther 2007, 321:158-64.
21. Weisel JW, Nagaswami C, Makowski L. Twisting of fibrin fibers limits their radial growth. Proc Natl Acad Sci USA 1987, 84:8991-5.